Heartflow, Inc. (HTFL) Spending and interest coverage
- R&D / revenue · 12 months: Value 39.53%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 11.17%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 39.53% | Research and development expense / revenue. Period ending 2026-06-30. $83.84M ÷ $212.07M × 100 ≈ 39.53% |
| Stock-based compensation / revenue · 12 months | 11.17% | Share-based compensation / revenue. Period ending 2026-06-30. $23.69M ÷ $212.07M × 100 ≈ 11.17% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 83.84M USD | Research and Development Expense |
| Revenue | 212.07M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 23.69M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -80.25M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $83.84M | $212.07M | $23.69M | $-80.25M | (m) | 39.53% | 11.17% | (m) | (m) |
| 2026-03-31 | $72.61M | $191.42M | $18.03M | $-76.07M | (m) | 37.94% | 9.42% | (m) | (m) |
| 2025-12-31 | $64.92M | $176.03M | $13.96M | $-64.07M | (m) | 36.88% | 7.93% | (m) | (m) |
| 2025-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $43.52M | $125.81M | $10.21M | $-61.22M | (m) | 34.59% | 8.12% | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $35.85M | $87.17M | $11.87M | $-72.91M | (m) | 41.13% | 13.62% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |
| PULSE BIOSCIENCES, INC. (PLSE) | United States | $3.696B | -24.47 |
| iRhythm Holdings, Inc. (IRTC) | United States | $3.651B | -281.06 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| AtriCure, Inc. (ATRC) | United States | $3.089B | |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |